SLE and LN market expected to reach $5.9bn across 7MM by 2034
A notable growth in the systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the seven major markets (7MM;…
Analyst Comment
Significant opportunities exist in the global pain market for novel mechanisms and modalities
Market instability expected from South Korea’s new pricing reform in 2026-2028
AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals
Have originator medicines’ list prices started to drop in the US?
The beginning of the end: Eliquis sales forecast to plummet as EU patent expiry nears
UK–US zero‑tariff deal pricing reforms position UK as global hub for new medicines
JPM26: Immunocore Signals Entry into type 1 diabetes
